Martina Diekmann

Mytide Therapeutics, Inc. is a peptide and biopolymer manufacturing and computational biology company based in Massachusetts. Mytide's focus is on eliminating the time-consuming and labor-intensive chemical and screening processes that prevent innovative therapeutics from reaching the clinic. The American company's quick-turn manufacturing technology, combined with AI-enabled predictive analytics, provides access to a novel peptide space for the discovery and therapeutic manufacturing of difficult-to-make natural and non-natural peptide and peptide conjugates. The company was founded by Dale Thomas and has been led by CEO Martina Diekmann since 2023.

Mytide Therapeutics, Inc. is a peptide and biopolymer manufacturing and computational biology company based in Massachusetts. Mytide's focus is on eliminating the time-consuming and labor-intensive chemical and screening processes that prevent innovative therapeutics from reaching the clinic. The American company's quick-turn manufacturing technology, combined with AI-enabled predictive analytics, provides access to a novel peptide space for the discovery and therapeutic manufacturing of difficult-to-make natural and non-natural peptide and peptide conjugates. The company was founded by Dale Thomas and has been led by CEO Martina Diekmann since 2023.

Mytide Therapeutics, Inc. is a peptide and biopolymer manufacturing and computational biology company based in Massachusetts. Mytide's focus is on eliminating the time-consuming and labor-intensive chemical and screening processes that prevent innovative therapeutics from reaching the clinic. The American company's quick-turn manufacturing technology, combined with AI-enabled predictive analytics, provides access to a novel peptide space for the discovery and therapeutic manufacturing of difficult-to-make natural and non-natural peptide and peptide conjugates. The company was founded by Dale Thomas and has been led by CEO Martina Diekmann since 2023.

Part of Biosynth Holding AG, vivitite LLC is a provider of custom peptides, antibody services, and catalog products for the life science and biotech industry. The company is based in Gardner, MA, with significant operations in KY. Vivitide was founded in 2019, and Martina Diekmann has been the CEO of the company since 2020. Committed to outstanding quality and customer service, vivitide provides a broad portfolio of custom peptide synthesis services, custom antibodies, catalog peptides, and biochemicals to academia, pharmaceutical, biotech, and diagnostic companies worldwide. Vivitite LLC was acquired by Biosynth Carbosynth, part of Biosynth Holding AG from April 08, 2022 on March 17, 2022.